Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 3/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.30 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.30 |
| ▸ | STS | P08842 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15408723 | 0.85 | ALDH1A1 (0.39) | SMN1; SMN2NR1D1TSHRALDH1A1PDE2A | |
| SCHEMBL15409223 | 0.83 | ALDH1A1 (0.36) | APLNRTP53GAASMN1; SMN2TSHR | |
| SCHEMBL15409446 | 0.80 | APLNR (0.34) | APLNRTP53GAASMN1; SMN2ALDH1A1 | |
| SCHEMBL15406876 | 0.80 | PDE1B (0.34) | APLNRTP53GAASMN1; SMN2TSHR | |
| SCHEMBL15413896 | 0.69 | NOS1 (0.39) | GAATSHRALDH1A1MAPK1PDE1B | |
| SCHEMBL15407268 | 0.69 | KDM4E (0.38) | APLNRNR1D1TSHRALDH1A1MAPK1 | |
| SCHEMBL18786333 | 0.69 | ALDH1A1 (0.38) | NR1D1ALDH1A1PDE1BPDE2ACYP19A1 | |
| SCHEMBL19281311 | 0.69 | TGFBR1 (0.33) | TP53SMN1; SMN2ALDH1A1MAPK1PDE1B | |
| SCHEMBL15406603 | 0.68 | MAPT (0.41) | TP53SMN1; SMN2NR1D1TSHRALDH1A1 | |
| SCHEMBL13644193 | 0.68 | NR1D1 (0.34) | NR1D1TSHRALDH1A1MAPK1PDE1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2872514-B1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-30 | — | — | EP | disclosed |
| US-9556178-B2 | Imidazotriazinecarbonitriles useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-31 | — | — | US | disclosed |
| US-20160108050-A1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-21 | — | — | US | disclosed |
| US-9273057-B2 | Imidazotriazinecarbonitriles useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150210697-A1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-07-30 | — | — | US | disclosed |
| EP-2872514-A1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2015-05-20 | — | — | EP | disclosed |
| US-20150065465-A1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-03-05 | — | — | US | disclosed |
| US-8940736-B2 | Imidazotriazinecarbonitriles useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-27 | — | — | US | disclosed |
| US-20140018319-A1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-01-16 | — | — | US | disclosed |
| WO-2014011974-A1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018319-A1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | ABL1, MAP4K2, MAP3K1 | APLNR 2886/4885TP53 698/4885GAA 3062/4885 |
| US-20150065465-A1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | ABL1, MAP4K2, MAP3K1 | APLNR 2886/4885TP53 698/4885GAA 3062/4885 |
| US-20150210697-A1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | ABL1, MAP4K2, MAP3K1 | APLNR 2886/4885TP53 698/4885GAA 3062/4885 |
| US-20160108050-A1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | ABL1, MAP4K2, MAP3K1 | APLNR 2886/4885TP53 698/4885GAA 3062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.